Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Dosing of CC-92480 and to Explore the Effect of Food on the Bioavailability of CC-92480 in Healthy Subjects

Next Previous
Search
Trial Profile

A Phase 1, Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Dosing of CC-92480 and to Explore the Effect of Food on the Bioavailability of CC-92480 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Apr 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mezigdomide (Primary)
  • Indications Multiple myeloma
  • Focus Pharmacokinetics
  • Sponsors Celgene Corporation

    • Most Recent Events

    • 17 Mar 2021 Plasma concentration from 62 healthy subjects from 2 phase 1 studies (NCT03803644 and NCT04211545) were used to develop a population PK model, presented at the 122nd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 06 May 2020 Status changed from recruiting to completed.
    • 29 Mar 2019 Planned number of patients changed from 52 to 42.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top